Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-01-04
2005-01-04
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C530S300000, C536S023720
Reexamination Certificate
active
06838084
ABSTRACT:
The present invention relates to a papillomavirus T-cell epitope having an amino acid sequence ILVPKVSGL (SEQ ID NO: 1), RLVWACVGV (SEQ ID NO: 2), HLFNRAGTV (SEQ ID NO: 3), YLRREQMFV (SEQ ID NO: 4), TLQANKSEV (SEQ ID NO: 5), ILEDWNFGL (SEQ ID NO: 6), SLWLPSEATVYL (SEQ ID NO: 7), NLASSNYFPT (SEQ ID NO: 8), TLTADVMTYI (SEQ ID NO: 9), YLPPVPSKV (SEQ ID NO: 10), YDLQFIFQL (SEQ ID NO: 11), ICWGNQLFV (SEQ ID NO: 12), FYNPDTQRL (SEQ ID NO: 13), MHGDTPTLH (SEQ ID NO: 14), ETTDLYCY (SEQ ID NO: 15), QAEPDRAHYN (SEQ ID NO: 16), SMVTSDAQI (SEQ ID NO: 17), and/or to a functionally active variant thereof, and also to their use in diagnostics and therapy.
REFERENCES:
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 5415995 (1995-05-01), Schoolnik et al.
patent: 5547846 (1996-08-01), Bartsch et al.
patent: 5629146 (1997-05-01), Dillner et al.
patent: 5629161 (1997-05-01), Müller et al.
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5747269 (1998-05-01), Rammensee et al.
patent: 6025163 (2000-02-01), Shamanin et al.
patent: 6183746 (2001-02-01), Urban et al.
patent: 2140591 (1995-07-01), None
patent: 0 375 555 (1990-06-01), None
patent: 0 386 734 (1990-09-01), None
patent: 0 451 550 (1991-10-01), None
patent: 2 279 651 (1994-06-01), None
patent: WO 9004790 (1990-05-01), None
patent: WO 9118294 (1991-11-01), None
patent: WO 9205248 (1992-04-01), None
patent: WO 9210513 (1992-06-01), None
patent: WO 9302184 (1993-02-01), None
patent: WO 9320844 (1993-10-01), None
patent: WO 9322338 (1993-11-01), None
patent: WO 9405792 (1994-03-01), None
patent: WO 9420137 (1994-09-01), None
patent: WO 9501374 (1995-01-01), None
patent: WO 9611272 (1996-04-01), None
patent: WO 9633737 (1996-10-01), None
patent: WO 9805790 (1998-02-01), None
patent: WO 9823752 (1998-06-01), None
patent: WO 9903885 (1999-01-01), None
patent: WO 9918220 (1999-04-01), None
patent: WO 9965522 (1999-12-01), None
Chan et al , Journal of Virology, Oct. 1992, vol. 66, No. 10, pp. 5714-5725.*
Altman et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes,”Science274:94-96 (1996).
Baker et al., “Structures of Bovine and Human Papillomaviruses,”Biophys. J. 60:1445-1456 (1991).
De Bruijn et al., “Mechanisms of Induction of Primary Virus-Specific Cytotoxic T Lymphocyte Responses,”Eur. J. Immunol. 22:3013-3020 (1992).
De Bruijn et al., “Peptide Loading of Empty Major Histocompatibility Complex Molecules on RMA-S Cells Allows the Induction of Primary Cytotoxic T Lymphocyte Responses,”Eur. J. Immunol. 21:2963-2970 (1991).
De Gruijl et al., “Immune Responses Against Human Papillomavirus (HPV) Type 16 Virus-Like Particles in a Cohort Study of Women with Cervical Intraepithelial Neoplasia 1. Differential T-Helper and IgG Responses in Relation to HPV Infection and Disease Outcome,”Journal of General Virology80:399-408 (1999).
Dunbar et al., “Direct isolation, Phenotyping and Cloning of Low-Frequency Antigen-Specific Cytotoxic T Lymphocytes From Peripheral Blood,”Current Biology8:413-416 (1998).
Feltkamp et al., “Vaccination with a Cytotoxic T Lymphocyte-Containing Peptide Protects Against a Tumor Induced by Human Papillomavirus Type 16-Transformed Cells,”Eur. J. Immunol. 23:2242.2249 (1993).
Gossen et al., “Inducible Gene Expression Systems for High Eukaryotic Cells,”Current Opinion in Biotechnology5:516-520 (1994).
Heino et al., “Human Papillomavirus Type 16 Capsids Expose Multiple Type-Restricted and Type-Common Antigenic Epitopes,”Journal of General Virology76:1141-1153 (1995).
Kast et al., “Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins,”Journal of Immunology152:3904-3912 (1994).
Krchnak et al., “Synthetic Peptides Derived From E7 Region of Human Papillomavirus Type 16 used as Antigens in ELISA,”Journal of General Virology71:2719-2724 (1990).
Müller et al., “Identification of Seroreactive Regions of the Human Papillomavirus Type 16 Proteins E4, E6, E7, and L1,”Journal of General Virology71:2709-2717 (1990).
Müller et al., “Chimeric Papillomavirus-Like Particles,”Virology234:94-111 (1997).
Nieland et al., “Chimeric Papillomavirus Virus-Like Particles Induce a Murine Self-Antigen-Specific Protective and Therapeutic Antitumor Immune Response,”Journal of Cellular Biochemistry71:145-152 (1999).
Parker et al., “Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains,”Journal of Immunology152:163-175 (1994).
Peng et al., “Papillomavirus Virus-Like Particles Can Deliver Defined CTL Epitopes to the MHC Class 1 Pathway,”Virology240:147-157 (1998).
Rudolf et al, “Induction of HPV16 Capsid Protein-Specific Human T Cell Responses by Virus-Like Particles,”Biol. Chem. 380:335-340 (1999).
Schäfer et al., “Immune Response to Human Papillomavirus 16 L1E7 Chimeric Virus-Like Particles: Induction of Cytotoxic T Cells and Specific Tumor Protection,”Int. J. Cancer81:881-888(1999).
Sijts et al., “Cytotoxic T Lymphocytes Against the Antigen-Processing-Defective RMA-S Tumor Cell Line,”Eur. J. Immunol.22:1639-1642 (1992).
Sijts et al., “Immunodominant Mink Cell Focus-Inducing Murine Leukemia Virus (MuLV)-Encoded CTL Epitope, Identified by Its MHC Class I-Binding Motif, Explains MuLV-Type Specificity of MCF-Directed Cytotoxic T Lymphocytes,”Journal of Immunology152:106-116 (1994).
Tsukui et al., “Interleukin 2 Production in Vitro by Peripheral Lymphocytes in Response to Human Papillomavirus-Derived Peptides: Correlation with Cervical Pathology,”Cancer Research56:3967-3974 (1996).
Zhou et al, “Definition of Linear Antigenic Regions of the HPV 16 L1 Capsid Protein Using Synthetic Virion-Like Particles,”Virology189:592-599 (1992).
Zwicker et al., “Cell-Cycle Regulation of Gene Expression by Transcriptional Repression,”TIG13:3-6 (1997).
Jochmus Ingrid
Nieland John
Clark & Elbing LLP
MediGene Aktiengesellschaft
Salimi Ali R.
LandOfFree
Cytotoxic T-cell epitopes of the papilloma virus l1-protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxic T-cell epitopes of the papilloma virus l1-protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic T-cell epitopes of the papilloma virus l1-protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3374205